1. Joint European Societies Recommendations on Prevention of Coronary Heart Disease in Clinical Practice. Summary of Recommendations by the Second Joint Task Force. Eur Heart J 1998; 19:1434-503

  2. Expert Panel on Detection, Evaluation and Treatment High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486

  3. Onat A: Türk halkında koroner kalp hastalığı sıklığının nedenleri ve bu bilginin risk değerlendirilmesi ile korunma açılarından büyük önemi. Türk Kardiyol Dern Arş 2001: 29:602-9

  4. Onat A: Halkımız için total kolesterol düzeyi normal üst sınırı neden mutlaka 180 mg/dl'ye çekilmeli. Türk Kardiyol Dern Arş 2001: 29:703-7

  5. Onat A: Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156:1-10

  6. Onat A, Keleş İ, Sansoy V ve ark: Yetişkinlerimizin 10-yıllık takibinde obezite göstergeleri artışta: Beden kitle indeksi erkeklerde koroner olayların bağımsız öngördürücüsü. Türk Kardiyol Dern Arş 2001: 29:430-6

  7. Mahley RW, Palaoğlu E, Atak Z, et al: Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-59

  8. Onat A, Yıldırım B, Erer B ve ark: Total kolesterol/HDL-kolesterol oranı koroner hastalığın en iyi lipid öngördürücüsü: Trigliserid ortalama düzeyimiz yılda 1 mg yükselme gösteriyor. Türk Kardiyol Dern Arş 2001:29: 334-43

  9. Onat A, Keleş İ, Çetinkaya A ve ark: On yıllık TEKHARF çalışması verilerine göre Türk erişkinlerinde koroner kökenli ölüm ve olayların prevalansı yüksek. Türk Kardiyol Dern Arş 2001; 29:8-19

  10. Onat A, Uysal Ö, Hergenç G: TEKHARF çalışması orijinal kohortunun Framingham risk fonksiyonuna göre değerlendirilmesi: halkımızın mutlak koroner riskinin yüksekliğine ilişkin bir ek kanıt. Türk Kardiyol Dern Arş 2001; 29:208-14

  11. Türk Kardiyoloji Derneği. Koroner Arter Hastalığı Yaklaşım ve Tedavi Kılavuzu. Türk Kardiyol Dern Arş 1999; 27:262-316

  12. Bersot TP, Pépin GM, Mahley RW: Guidelines for treatment of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Am Heart J 2002; (baskıda)

  13. Mahley RW, Pépin GM, Bersot TP, Palaoğlu KE, Özer K: Türk Kalp Çalışması'nda yeni sonuçlar: Plazma lipidleri ve yüksek yoğunluklu lipoprotein düzeyleri düşüklüğünde tedavi için rehber öneriler. Türk Kardiyol Dern Arş 2002: 30:93-103

  14. Lidker PM: High-sensitivity C-reactive protein: postential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8

  15. Onat A, Sansoy V: Halkımızda koroner hastalığın başsuçlusu metabolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyol Dern Arş 2002;30:8-15

  16. LaRosa JC, Hle J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340-6

  17. Maron DJ, Fazio S, Linton FM: Current perspectives on statins. Circulation 2000; 101: 207-13

  18. Crouse JR III: Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243-8

  19. Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3:83-92

  20. Tavintharan S, Kashyap ML: The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 2001; 3:74-82

  21. Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998;82:82U-84U; discussion 85U-86U

  22. Hulley S, Grady S, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff FE: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-13

  23. Herrington DM, Reboussin DM, Brosnihan KB, et al: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Eng J Med 2000; 343:522-9

  24. Kannel WP: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-76

  25. Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB: Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol,1989;130:469-80

  26. Herlitz J, Brandrup-Wognsen G, Karlson BW, Sjoland H, Karlsson T, Caidahl K, Hartford M, Haglid M: Mortality, risk indicators, mode and place of death and symptoms of angina pectoris in the five years after coronary artery bypass grafting in patients with and without a history of hypertension. Blood Press,1999; 8:200-6

  27. Vasan RS, Larson MG, Leip EG, Evans JC, O'Donnell CJ, Kannel WB, Levy D: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Eng J Med 2001; 345:1291-7

  28. Türk Kardiyoloji Derneği Ulusal Hipertansiyon Tedavi ve Takip Kılavuzu. Türk Kardiyol Dern Arş 2000;28:335-97

  29. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997;157:2413-46

  30. Guidelines Subcommittee of the World Health Organization: World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83

  31. Frishman WH: Postinfarction survival: role of b-adrenergic blockade. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott Raven;1996:1205-14

  32. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7

  33. Gottlieb SS, MacCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97

  34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75

  35. Opie LH, Scholl R: Evidence-based evaluation of calcium channel blockers for hypertension. J Am Coll Cardiol 2002;39:315-22

  36. Gueyffler F, Boutitie F, Boissel JP, et al: Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized controlled trials. Ann Intern Med 1997;126:761-67

  37. Staessen JA, Fagard R, Thijis L, et al: Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly (SYST-EUR). Lancet 1997;350:757-64

  38. Psaty B, Smith N, Siscovick D, et al: Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and a meta-analysis. JAMA 1997;277:739-45

  39. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997;15:105-15

  40. Pahor M, Psaty BM, Alderman MH, et al: Health outcomes associated with calcium antagonists compared with orher first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000;356:1949-56

  41. Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72

  42. Jespersen CM, Hansen JF, for the Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish Verapamil Infarction Trial II (DAVIT II). The Danish Study Group on Verapamil in Myocardial Infarction. J Hum Hypertens 1994;8:85-8

  43. Hansson L, Hedner T, Lund-Johansen P, et al: Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65

  44. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;356:1955-64

  45. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk population. N Engl J Med 2000;342:145-53

  46. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Study. Lancet 2000;355:253-9

  47. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9

  48. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001.345:870-78

  49. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60

  50. Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003

  51. Wilhemsson C, Elmfeldt D et al: Smoking and myocardial infarction. Lancet 1975;1:415-19

  52. Pasternak RC, Grundy TM, Levy D, Thompson PD: Task Force 3. Spectrum of risk factors for coronary heart disease. JACC 1996;27:978-990

  53. Joseph AM, Norman SM, Ferry LH, et al: The safety of transdermal nicotine as an aid to smoking sessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8

  54. Pipe AL: Smoking cessation: closing the gap between guidelines and practice. CVD Prevention 1999;2:18-22

  55. Thorndike AN, Rigotti NA, Stafford RS, et al: National patterns in the treatment of smokers by physicians JAMA 1998;279:604-8

  56. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors and 12-yr mortality for men screened in the Multiple Risk Factors Intervention Trial. Diabetes Care 1993;16:434-44

  57. Kannel WB: Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100-7

  58. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999;22(suppl I):S5-19

  59. Baron AD: Impaired glucose tolerance as a disease. Am J Cardiol 2001;88 (S):16-19

  60. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53

  61. The Diabetes Control and Complications Trial Reseach Group. The effect of intensive treatment of diabetes on the devolopment and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329: 977-86

  62. UK Prospective Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. Br Med J 1998;317:703-13

  63. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9

  64. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet 2001;357:905-10

  65. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(supp2):S51-209

  66. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO; 2000

  67. National Task Force on Obesity. Owerweight, obesity and health risk. Arch Intern Med 2000;160:898-904

  68. Rao SV, Donahue M, Pi-Sunyer X, Fuster V: Obesity as a risk factor in coronary artery disease. Am Heart J 2001;142:1102-7

  69. Pouliot MC, Depres JP, Nadeau A, et al: Visceral obesity in man. Associations with glucose intolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41:826-34

  70. Lee IM, Hsieh CC, Paffenbarger RS Jr: Exercise intensity and longevity in man: the Harvard Alumni Health Study. JAMA 1995;273:1179-84

  71. Pate RR, Pratt M, Blair SN, et al: Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273;402-7

  72. Scholler DA, Shay K, Kushner RF: How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr 1997;66:239-46

  73. Williams PT: High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Eng J Med 1996;334:1298-1303

  74. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RD.Jr: Physical activity and reduced occurence of non-insulin-dependent diabetes mellitus. N Eng J Med 1991;325:147-52

  75. Kelley GA, Kelley KS: Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2000;35:838-43

  76. Chakravarthy MV, Joyner MJ, Booth FW: An obligation for primary care physicians to prescribe physical activity to sedantary patients to reduce the risk of chronic health conditions. Mayo Clin Proc 2002;77:165-73

  77. Hambrecht R, Wolf A, Gielen S, et al: Effect of exercise on coronary endotelial function in patients with coronary artery disease. N Eng J Med 2000;342;454-60

  78. Stratton JR, Chandler WL, Schwartz RS, et al: Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991;83:1692-7

  79. Kramsch DM, Aspen AJ, Abramowitz BM, et al: Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. N Eng J Med 1981;305:1483-9

  80. Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA: Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995;273:1093-8

  81. Coats AJ: Exercise rehabilitation in chronic heart failure. J Am Coll Cardiol 1993;22:172A-177A

  82. Franklin BA, Bonzheim K, Gordon S, et al: Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16-year follow-up. Chest 1998;114:902-6

  83. Siscovick DS, Weiss NS, Fletcher RH, et al: The incidence of primary cardiac arrest during vigorous exercise. N Eng J Med 1984;311:874-7

  84. Hemingway H, Marmot M: Evidence based cardiology: Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ 1999; 318:1460-7

  85. Miller TQ, Smith TW, Turner CW, Guijarro ML, Hallet AJ: A meta-analytic review of research on hostility and physical health. Psychol Bull 1996;119:322-348

  86. Mittleman MA, Maclure M, Sherwood JB, et al: Determinants of Myocardial Infarction Onset Study Investigators. Triggering of acute myocardial infarction onset by episodes of anger. Circulation 1995;92:1720-25

  87. Ziegelstein RC: Depression in patients recovering from a myocardial infarction. JAMA 2001; 286: 1621-27

  88. Berkman LF, Leo-Summers L, Horwitz RI: Emotional support and survival after myocardial infarction: a prospective, population-based study of the elderly. Ann Intern Med 1992;117:1003-9

  89. Linden W, Stossel C, Maurice J: Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996;156:745-52

  90. Smith SC: Prevention conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Tests for silent and inducible ischemia. Circulation 2000;101: e12

  91. Greenland P: Prevention conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden. Circulation 2000;101: e16

  92. Greenland P, Smith SC, Grundy SM, et al: Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-67

  93. Pearson TA: New tools for coronary risk assessment. What are their advantages and limitations? Circulation 2002;105:886-92

  94. Mark DB: An Overview of Risk Assessment in Coronary Artery Disease. Am J Cardiol 1994;73:19B-23B

  95. Grundy SM: Primary Prevention of Coronary Heart Disease. Integrating Risk Assessment With Intervention. Circulation 1999;100:988-98

  96. Coronary Artery Calcification: Pathophysiology, Epidemiology, Imaging Methods and Clinical Implications. A Statement for Healt Professionals from the American Heart Association. Circulation 1996;94:1175-92

  97. ACC/AHA Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. Circulation 2000;102:126-40

  98. Rumberger JA: Electron Beam Computed Tomographic Coronary Calcium Scanning: A Review and Guidelines for use in Asymptomatic Persons. Mayo Clin Proc 1999;74:243-52

  99. Grundy SM: Coronary Calcium as a Risk Factor: Role in Global Risk Assessment. JACC 2001;37:1512-15

  100. ACC/AHA guidelines for exercise testing. JACC 1997;30:260-315

  101. ACC/AHA Task Force Report: Guidelines for clinical use of cardiac radionuclide imaging. JACC 1995:25;521-47

  102. Krauss RM, Eckel RH, Howard B, et al: AHA Scientific Statement. AHA Dietary Guidelines. Circulation 2000;102:2284-99

  103. Pinhas-Hamiel O, Dolan LM, Daniels SR et al: Increased insidence of non-insulin dependent diabetes mellitus among adolescents. J Pediatr 1996;128:608

  104. Davis PH, Dawson JD, Riley WA, Lauer RM: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104: 2815-

  105. Stein DT, Stevenson BE, Chester MW et al: The insulinotropic potency of fatty acids is influenced profoundly by their chain lenght and degree of saturation. J Clin Invest 1997;100:398

  106. Louherauta AM, Porkkala-Sarataho EK, Nyyssonen MK, et al: Linoleic acid intake and susceptibility of very low density and low density lipoproteins to oxidation in men. Am J Clin Nutr 1996;63:698

  107. Roche HM, Gibney MJ: Long chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 1999;34:259

  108. Harris WS: n-3 fatty acids and human lipoprotein metabolism: an update. Lipids 1999; 34:S257

  109. Mori TA, Beilin LJ, Burke V, et al: Interactions between dietary fat, fish and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997; 17:279

  110. Goodnight SH, Harris WS, Conner WE: The effects of dietary n-3 fatty acids on platelet composition and function in man. A prospective, controlled study. Blood 1981;58:880

  111. Hiral A, Hamazaki T, Terona T et al: Eicosapentanoic acid and platelet function in Japanese. Lancet 1980; 2:1132

  112. Albert CM, Hennekens CH, O'Donnell CJ, et al: Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23

  113. Siscovick DS, Raghunathan TE, King I et al: Dietary intake and cell membrane levels of long chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363

  114. JX Kang, A Leaf: Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000, 71 Suppl. 202S

  115. GISSI-Prevenzione Investigators. Dietary I supplementation with n-3 polyunsatured fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial. Lancet 1999;354:447

  116. Burr ML, Fehily AM, Gilbert JF, et al: Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet, 1989;334:757

  117. Guallar E, Aro A, Jimenez FJ et al: Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Arterioscler Thromb Vasc Biol 1999;19:1111

  118. Starc TJ, Shea S, Cohn LC et al: Greater dietary intake of simple carbonhydrate is associated with lower concentrations of high density lipoprotein cholesterol in hypercholesterolemic children. Am J Clin Nutr. 1998;67:1147

  119. Brown L, Rosner B, Willet WW et al: Cholesterol lowering effects of dietary fiber: a meta analysis. Am J Clin Nutr 1999;69:30

  120. Coats AJ: The potential role of soluble fibre in the treatment of hypercholesterolemia. Postgrad. Med 1998;74:391

  121. Omenn GS, Goodman GE, Thornquist MD et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150

  122. Yusuf S, Dagenais G, Pogue J et al: Vitamin E supplementation and cardiovascular events in high risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154

  123. Hunink MG, Goldman L, Tosteson AN, et al: The recent decline in mortality from coronary heart disease, 1980-1990:the effect of secular trends in risk factors and treatment. JAMA 1997;272:535-42

  124. US Department of Health and Human Services. The health benefits of smoking cessation. Department of Health and Human Services Publication No.(CDC) 1990;90:8416

  125. Fogard R: Physical fitness and blood pressure. J Hypertens 1993;11(Suppl 5):S47-S52

  126. The Trials of Hypertension Prevention Collaborative Research Group: the effects of non-pharmacologic interventions on blood pressure of persons with high normal levels. JAMA 1992;267:1213-20

  127. World Hypertension League. Alcohol and hypertension: implications for management. Bull WHO 1991;69:377-82

  128. Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost-effectiveness of assessment and management of risk factors. JACC 1996;27:964-1047

  129. Meltzer MI: Introduction to health economics for physicians. Lancet 2001;358;993-8

  130. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Full Report "Manuscript Version". Bethesda, MD: National Heart, Lung, and Blood Institute, 2001

  131. Prosser LA, Stinnet AA, Goldman PA, et al: Cost-effectiveness of cholesterol-lowering therapies according to selected patient charecteistics. Ann Intern Med 2000;132:769-79

  132. Caro J, Hay JW, Pitt B, et al: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Med 1996;78:409-14

  133. Tengs TO, Wallace A: One thousand health-related quality of life estimates. Med Care 2000;38:583-637

  134. Prevention of coronary heart disease in clinical practice. Recommendation of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-1503

  135. Jackson R: Absolute 5-year risk of a cardiovascular event (newly diagnosed angina, myocardial infaction, coronary heart disease, death, stroke, or TIA) based on Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. National Health Committee, Ministry of Health, Wellington, 1995

  136. Cummings SR, Rubin SM, Oster G: The cost-effectiveness of counselling smokers to quit. JAMA 1989;261:75-9

  137. Schwartz JS: Comparative economic data regarding lipid lowering drugs. Am Heart J 1999;137:S97-S104

  138. The New Zealand National Health Committee: Strategies for the Primary Prevention of Cardiovascular Disease. A report to the New Zealand National Health Committee. January 1998

  139. Pederson TR, Kjekshus J, Berg K, et al: Cholesterol lowering and the uses of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-1802

  140. Johannesson M, Jönsson B, Kjekshus J, et al: Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary artery disease. N Engl J Med 1997;336:332-36

  141. Tsevet J, Kuntz KM, Orav EJ, et al: Cost-effectiveness of pravastatin therapy for survivors of myocardial infaction with average cholesterol levels. Am Heart J 2001;141:727-34

  142. Muls E, Van Gause E, Closen MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and United States of a projected risk model. Atherosclerosis 1998;137(Suppl):S111-S116

  143. Downs JR, Clearfield M, Weis S, et al: For the AFSCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels; results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22

  144. Onat A, Yıldırım B, Uslu N ve ark: Türk erişkinlerinde plasma lipoprotein ve apolipoproteinleri: Genel düzeyler, risk faktörleri ile ilişkileri ve kadınlarda HDL-K'nın koroner risk belirleyiciliği. Türk Kardiyol Dern Arş 1999;27:72-9

  145. Onat A, Uysal Ö, Hergenç G: TEKHARF çalışması orijinal kohortunun Framingham risk fonksiyonuna göre değerlendirilmesi: Halkımızın mutlak koroner riskinin yüksekliğine ilişkin bir ek kanıt. Türk Kardiyol Dern Arş 2001;29:208-1